Investor Lawsuit Pending Against Directors of Regeneron Pharmaceuticals, Inc. – Contact Shareholders Foundation for Information

Investor in NASDAQ:REGN Shares Files Lawsuit Against Regeneron Pharmaceuticals Directors

In a recent development, an investor in NASDAQ:REGN shares has filed a lawsuit against certain directors of Regeneron Pharmaceuticals, Inc. The lawsuit alleges breaches of fiduciary duty and seeks to recover damages for the benefit of the company from the alleged wrongdoers.

The plaintiff claims that several directors, including a majority of the current board members, collectively sold over $650 million in Regeneron stock through the exercise of stock options. The lawsuit aims to hold these individuals accountable for their actions and recover losses incurred by the company.

The lawsuit stems from allegations of improper behavior by Regeneron, with origins dating back to a previous lawsuit filed in June 2020. In that case, the United States accused Regeneron of improperly covering copays for Medicare beneficiaries through charitable donations, in violation of federal laws.

Both cases are currently pending, and investors who purchased shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) are encouraged to contact the Shareholders Foundation, Inc. for more information on their options.

The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and settlement claim filing service that provides research on shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal news related to the stock market. Investors should note that the Shareholders Foundation, Inc. is not a law firm and does not provide legal advice.

For more information on this lawsuit and how it may impact investors, please contact the Shareholders Foundation, Inc. at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.

Source: Shareholders Foundation, Inc.